Saturday 17 October 2026
Export PDSB’s income statement to Excel — free account
PDS Biotechnology Corporation
PDSB Healthcare Biotechnology
In the quarter to June 2026, EPS grew 14.3%, free cash flow grew 69.3% and total debt fell 66.6%, each against the same quarter a year earlier.
1.12
0.18
−13.85%
Follow PDSB
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
16.06 | 6.92 | 0.06 | 5.18 | 9.28 | 17.80 | 7.79 | 4.33 | 2.64 | 2.98 |
Net Debt/EBITDA |
2.33 | 1.31 | 0.02 | 0.58 | 1.90 | 3.03 | 1.22 | 0.87 | 0.92 | 0.50 |
Debt/Assets |
13.48% | 22.09% | 18.25% | 0.00% | 1.59% | 0.34% | 30.11% | 33.05% | 20.43% | 38.56% |
Debt/Equity |
0.17 | 0.33 | (0.01) | 0.00 | 0.02 | 0.00 | 0.53 | 0.75 | 0.49 | 1.27 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.83 | 0.80 | 0.41 | 2.58 | 0.89 | 0.74 | 0.63 | 0.78 | 0.93 | 0.80 |
Capex/Depreciation |
(2.58) | (0.58) | 0.00 | 2.79 | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 |
Interest Coverage |
(32.83) | (23.84) | (1,012.83) | (626.03) | (270.95) | (4,985.88) | (31.65) | (10.23) | (7.77) | (5.91) |
| (36.67%) | (67.08%) | (12.72%) | (145.33%) | (76.48%) | (37.46%) | (76.21%) | (122.46%) | (166.65%) | (244.16%) | |
| (31.69%) | (49.98%) | (8.27%) | (95.51%) | (65.43%) | (34.50%) | (56.66%) | (62.97%) | (71.81%) | (90.95%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(37.30%) | (63.89%) | 218.26% | (59.83%) | (54.84%) | (26.82%) | (60.81%) | (94.26%) | (133.80%) | (182.60%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(22.78) | (26.90) | (0.47) | (3.66) | (0.79) | (0.49) | (0.90) | (1.09) | (0.96) | (0.60) |
Cash per Share |
73.72 | 57.95 | 0.03 | 2.50 | 1.72 | 2.55 | 2.58 | 1.83 | 1.14 | 0.58 |
Shareholders Equity per Share |
61.86 | 41.04 | (0.62) | 2.40 | 1.62 | 2.47 | 1.54 | 0.84 | 0.52 | 0.20 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
61.86 | 41.04 | (0.62) | 2.40 | 1.62 | 2.47 | 1.54 | 0.84 | 0.52 | 0.20 |
Free Cash Flow |
(32.88) | (40.89) | (1.57) | (17.80) | (13.15) | (12.49) | (25.71) | (33.64) | (35.06) | (27.75) |
Working Capital |
100.67 | 76.19 | (1.79) | 11.68 | 27.07 | 63.08 | 66.66 | 45.43 | 27.97 | 18.77 |
Capital Expenditures |
(0.69) | (0.19) | — | 0.28 | — | — | — | — | (0.03) | — |
Net Current Asset Value |
85.72 | 58.80 | (2.11) | 11.68 | 26.58 | 62.85 | 43.47 | 25.80 | 18.70 | 7.01 |
| Other line items | ||||||||||
Quick Ratio |
15.92 | 6.84 | 0.05 | 4.35 | 8.82 | 17.37 | 7.52 | 4.15 | 2.44 | 2.82 |
Depreciation/Fixed assets |
0.08 | 0.09 | 2.34 | 4.66 | 2.89 | 54.00 | 0.44 | 5.29 | 8.57 | 13.43 |
Cash ROIC |
(15.61%) | (23.92%) | 81.22% | (74.60%) | (23.29%) | (9.70%) | (18.23%) | (32.87%) | (50.11%) | (58.15%) |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(22.30) | (26.78) | (0.47) | (3.71) | (0.79) | (0.49) | (0.90) | (1.09) | (0.96) | (0.60) |
Capex per Share |
(0.48) | (0.12) | 0.00 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
3.03 | 3.92 | 2.84 | 1.25 | 1.31 | 1.36 | 1.26 | 4.10 | 4.33 | 2.63 |
Average Assets |
122.50 | 101.77 | 46.39 | 7.33 | 22.69 | 49.04 | 72.10 | 68.20 | 52.37 | 37.93 |
Average Common Equity |
105.88 | 75.82 | 30.15 | 4.82 | 19.41 | 45.17 | 53.61 | 35.07 | 22.57 | 14.13 |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | — | — | — | — | 0.00 | — |
Columns are period end dates